WO2001053455A3 - Novel nucleic acids and polypeptides - Google Patents

Novel nucleic acids and polypeptides Download PDF

Info

Publication number
WO2001053455A3
WO2001053455A3 PCT/US2000/035017 US0035017W WO0153455A3 WO 2001053455 A3 WO2001053455 A3 WO 2001053455A3 US 0035017 W US0035017 W US 0035017W WO 0153455 A3 WO0153455 A3 WO 0153455A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/035017
Other languages
French (fr)
Other versions
WO2001053455A2 (en
Inventor
Y Tom Tang
Chenghua Liu
Radoje T Drmanac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyseq Inc
Original Assignee
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/596,196 external-priority patent/US6586390B1/en
Priority claimed from US09/653,274 external-priority patent/US6635742B1/en
Application filed by Hyseq Inc filed Critical Hyseq Inc
Priority to AU27348/01A priority Critical patent/AU2734801A/en
Priority to EP00990304A priority patent/EP1254256A4/en
Priority to US10/296,115 priority patent/US20040053248A1/en
Priority to CA002395736A priority patent/CA2395736A1/en
Publication of WO2001053455A2 publication Critical patent/WO2001053455A2/en
Priority to US10/128,558 priority patent/US20040219521A1/en
Publication of WO2001053455A3 publication Critical patent/WO2001053455A3/en
Anticipated expiration legal-status Critical
Priority to US10/243,552 priority patent/US20030224379A1/en
Priority to US10/302,689 priority patent/US20080050393A1/en
Priority to US10/496,905 priority patent/US20050192215A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.
PCT/US2000/035017 1998-12-03 2000-12-22 Novel nucleic acids and polypeptides Ceased WO2001053455A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU27348/01A AU2734801A (en) 1999-12-23 2000-12-22 Novel nucleic acids and polypeptides
EP00990304A EP1254256A4 (en) 1999-12-23 2000-12-22 NOVEL NUCLEIC ACID AND POLYPEPTIDE
US10/296,115 US20040053248A1 (en) 2000-12-22 2000-12-22 Novel nucleic acids and polypeptides
CA002395736A CA2395736A1 (en) 1999-12-23 2000-12-22 Novel nucleic acids and polypeptides
US10/128,558 US20040219521A1 (en) 2000-01-21 2002-04-22 Novel nucleic acids and polypeptides
US10/243,552 US20030224379A1 (en) 2000-01-21 2002-09-12 Novel nucleic acids and polypeptides
US10/302,689 US20080050393A1 (en) 1998-12-03 2002-11-22 Novel nucleic acids and polypeptides
US10/496,905 US20050192215A1 (en) 2000-01-21 2002-12-02 Methods and materials relating to novel polypeptides and polynucleotides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47127599A 1999-12-23 1999-12-23
US09/471,275 1999-12-23
US48872500A 2000-01-21 2000-01-21
US09/488,725 2000-01-21
US55231700A 2000-04-25 2000-04-25
US09/552,317 2000-04-25
US09/596,196 US6586390B1 (en) 2000-01-21 2000-06-17 Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
US09/653,274 US6635742B1 (en) 2000-01-25 2000-08-31 Antibodies specific for semaphorin-like polypeptides

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US55231700A Continuation-In-Part 1999-12-23 2000-04-25
PCT/US2001/002687 Continuation-In-Part WO2001054477A2 (en) 1998-12-03 2001-01-25 Novel nucleic acids and polypeptides

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US549901A Continuation-In-Part 2000-01-21 2001-12-03
US8464302A Continuation-In-Part 1998-12-03 2002-02-26
US10/128,558 Continuation-In-Part US20040219521A1 (en) 2000-01-21 2002-04-22 Novel nucleic acids and polypeptides
US10/243,552 Continuation-In-Part US20030224379A1 (en) 2000-01-21 2002-09-12 Novel nucleic acids and polypeptides

Publications (2)

Publication Number Publication Date
WO2001053455A2 WO2001053455A2 (en) 2001-07-26
WO2001053455A3 true WO2001053455A3 (en) 2002-05-02

Family

ID=27541704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035017 Ceased WO2001053455A2 (en) 1998-12-03 2000-12-22 Novel nucleic acids and polypeptides

Country Status (1)

Country Link
WO (1) WO2001053455A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7344880B2 (en) 1998-04-24 2008-03-18 Genentech, Inc. Nucleic acid encoding PRO9912 polypeptides
US7414112B2 (en) 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
ES2289630T3 (en) * 1999-03-08 2008-02-01 Genentech, Inc. COMPOSITIONS AND PROCEDURES FOR TUMORS DIAGNOSIS.
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2000073468A1 (en) 1999-05-28 2000-12-07 Immunex Corporation Novel murine and human kinases
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
AU1238201A (en) * 1999-10-27 2001-05-08 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7365157B2 (en) 1999-12-23 2008-04-29 Genentech, Inc. PRO9912 polypeptides
US7164001B2 (en) 2000-01-20 2007-01-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001081557A2 (en) * 2000-04-25 2001-11-01 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
WO2001092301A2 (en) * 2000-05-26 2001-12-06 Indiana University Advanced Research And Technology Institute Placc, a novel human c-c chemokine isolated from placenta
US20020019028A1 (en) * 2000-06-13 2002-02-14 Kabir Chaturvedi Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
AU2001268053A1 (en) * 2000-07-05 2002-01-14 Eli Lilly And Company Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
EP1307557A2 (en) 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
EP1329511A4 (en) 2000-09-19 2005-01-19 Kyowa Hakko Kogyo Kk POLYPEPTIDE HAVING PHOSPHOLYPASE A2 ACTIVITY
AU2001294744A1 (en) * 2000-09-26 2002-04-08 Ceptyr, Inc. Dsp-16 dual-specificity phosphatase
CA2423677A1 (en) * 2000-10-04 2002-04-11 Curagen Corporation Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
US6911336B2 (en) 2000-10-18 2005-06-28 Immunex Corporation GNK interacting amino acid decarboxylase and methods of use thereof
WO2002038764A2 (en) * 2000-11-10 2002-05-16 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US7153678B2 (en) 2000-12-20 2006-12-26 Bristol-Myers Squibb Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
US20020102637A1 (en) * 2000-12-21 2002-08-01 Chunhua Yan Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
WO2003031568A2 (en) * 2001-08-17 2003-04-17 Incyte Genomics, Inc. Intracellular signaling molecules
JP3740043B2 (en) * 2001-09-14 2006-01-25 アテナ ダイアグナスティクス，インコーポレイテッド Diagnosis and treatment of spinocerebellar degeneration (EAOH) based on aprataxin gene
WO2003025168A1 (en) * 2001-09-17 2003-03-27 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1440089A2 (en) * 2001-11-01 2004-07-28 Amersham plc Human angiomotin-like protein 1
US7151162B2 (en) 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
EP1483381A2 (en) * 2002-03-14 2004-12-08 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
US20060088835A1 (en) * 2002-04-05 2006-04-27 Pickard Benjamin S Schizophrenia associated genes
CA2481507A1 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP2275573A1 (en) * 2002-06-28 2011-01-19 Imclone LLC Antibodies for treating and diagnosing gastric adenocarcinoma
CN1681835A (en) * 2002-08-14 2005-10-12 株式会社Lg生命科学 Gene families associated with stomach cancer
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
JP4634371B2 (en) 2003-03-27 2011-02-16 ピーティーシー セラピューティクス，インコーポレーテッド Methods for identifying compounds that target tRNA splicing endonucleases and their use as antiproliferative agents
EP1613159A4 (en) 2003-03-27 2007-08-01 Ptc Therapeutics Inc Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-fungal agents
CA2531321A1 (en) * 2003-07-02 2005-01-13 Ptc Therapeutics, Inc. Rna processing protein complexes and uses thereof
US20070202567A1 (en) * 2003-09-27 2007-08-30 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Arginyl Aminopeptidase Rnpep (Rnpep)
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
CA2574791A1 (en) 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DE102004059781A1 (en) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Use of serum / glucocorticoid-regulated kinase
US9540427B2 (en) * 2007-05-30 2017-01-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide-based stat inhibitor
EP3058986B1 (en) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2020139866A2 (en) * 2018-12-27 2020-07-02 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EST [online] NATIONAL HUMAN GENOME INSTITUTE, (BETHESDA, MD, USA); 13 October 1999 (1999-10-13), JIA ET AL.: "SGAP: The skeletal genome anatomy project", XP002944982, Database accession no. AW068570 *
See also references of EP1254256A4 *
WATSON ET AL.: "The science used in the recombinant DNA industry. Recombinant DNA; A short course", 1983, W.H. FREEMAN AND COMPANY, NEW YORK, XP002944983 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8958881B2 (en) 2005-08-19 2015-02-17 Brainsgate Ltd. Neuroprotective electrical stimulation

Also Published As

Publication number Publication date
WO2001053455A2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2003080795A3 (en) Novel nucleic acids and secreted polypeptides
WO2001002571A3 (en) An interleukin-1 receptor antagonist and uses thereof
WO2005049806A3 (en) Novel nucleic acids and polypeptides
WO2002044340A3 (en) Novel nucleic acids and polypeptides
WO2001053453A8 (en) Novel bone marrow nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2395736

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000990304

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000990304

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10296115

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000990304

Country of ref document: EP